SciBase Holding AB (publ) (SCIB.ST)
SEK 0.37
(-6.03%)
SEK 0.37
(-6.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 16.03 Million SEK | 42.74% |
| 2022 | 11.23 Million SEK | 70.77% |
| 2021 | 6.57 Million SEK | 31.58% |
| 2020 | 5 Million SEK | -1.19% |
| 2019 | 5.06 Million SEK | 41.1% |
| 2018 | 3.58 Million SEK | 47.82% |
| 2017 | 2.42 Million SEK | 9.28% |
| 2016 | 2.22 Million SEK | 2055.34% |
| 2015 | 103 Thousand SEK | 117.85% |
| 2014 | -577 Thousand SEK | -312.14% |
| 2013 | -140 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 4.59 Million SEK | 8.51% |
| 2024 Q1 | 4.23 Million SEK | -0.12% |
| 2023 Q2 | 3.32 Million SEK | -6.08% |
| 2023 FY | 16.03 Million SEK | 42.74% |
| 2023 Q4 | 4.23 Million SEK | -14.25% |
| 2023 Q3 | 4.94 Million SEK | 48.69% |
| 2023 Q1 | 3.53 Million SEK | 16.15% |
| 2022 Q1 | 2.67 Million SEK | 29.12% |
| 2022 Q4 | 3.04 Million SEK | 5.58% |
| 2022 FY | 11.23 Million SEK | 70.77% |
| 2022 Q2 | 2.63 Million SEK | -1.65% |
| 2022 Q3 | 2.88 Million SEK | 9.7% |
| 2021 Q1 | 1.34 Million SEK | -10.6% |
| 2021 FY | 6.57 Million SEK | 31.58% |
| 2021 Q4 | 2.07 Million SEK | 9.69% |
| 2021 Q3 | 1.88 Million SEK | 48.54% |
| 2021 Q2 | 1.27 Million SEK | -5.78% |
| 2020 Q1 | 1.34 Million SEK | -16.93% |
| 2020 FY | 5 Million SEK | -1.19% |
| 2020 Q4 | 1.5 Million SEK | 25.33% |
| 2020 Q3 | 1.2 Million SEK | 28.36% |
| 2020 Q2 | 938 Thousand SEK | -30.47% |
| 2019 FY | 5.06 Million SEK | 41.1% |
| 2019 Q4 | 1.62 Million SEK | 56.76% |
| 2019 Q3 | 1.03 Million SEK | -10.3% |
| 2019 Q2 | 1.15 Million SEK | -7.3% |
| 2019 Q1 | 1.24 Million SEK | 17.88% |
| 2018 Q2 | 915 Thousand SEK | 1.78% |
| 2018 Q4 | 1.05 Million SEK | 47.83% |
| 2018 Q1 | 899 Thousand SEK | 51.09% |
| 2018 FY | 3.58 Million SEK | 47.82% |
| 2018 Q3 | 715 Thousand SEK | -21.86% |
| 2017 FY | 2.42 Million SEK | 9.28% |
| 2017 Q2 | 700 Thousand SEK | 50.54% |
| 2017 Q4 | 595 Thousand SEK | -10.66% |
| 2017 Q1 | 465 Thousand SEK | -31.42% |
| 2017 Q3 | 666 Thousand SEK | -4.86% |
| 2016 Q1 | 280 Thousand SEK | 29.03% |
| 2016 Q3 | 704 Thousand SEK | 26.16% |
| 2016 Q2 | 558 Thousand SEK | 99.29% |
| 2016 Q4 | 678 Thousand SEK | -3.69% |
| 2016 FY | 2.22 Million SEK | 2055.34% |
| 2015 Q3 | 175 Thousand SEK | 155.21% |
| 2015 Q2 | -317 Thousand SEK | -1232.14% |
| 2015 Q1 | 28 Thousand SEK | 114.66% |
| 2015 FY | 103 Thousand SEK | 117.85% |
| 2015 Q4 | 217 Thousand SEK | 24.0% |
| 2014 Q3 | -350 Thousand SEK | -1246.15% |
| 2014 Q4 | -191 Thousand SEK | 45.43% |
| 2014 Q2 | -26 Thousand SEK | -160.0% |
| 2014 Q1 | -10 Thousand SEK | 0.0% |
| 2014 FY | -577 Thousand SEK | -312.14% |
| 2013 FY | -140 Thousand SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -202.756% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 94.665% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 94.665% |
| Arcoma AB | 11.07 Million SEK | -44.856% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 88.543% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.124% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 93.578% |
| CellaVision AB (publ) | 463.04 Million SEK | 96.537% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -435.102% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 156.44% |
| C-Rad AB (publ) | 66.01 Million SEK | 75.707% |
| Duearity AB (publ) | -4.17 Million SEK | 483.844% |
| Dignitana AB (publ) | 58.97 Million SEK | 72.805% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 138.366% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.881% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 131.935% |
| Iconovo AB (publ) | 17.57 Million SEK | 8.765% |
| Integrum AB (publ) | 690.56 Thousand SEK | -2222.311% |
| Luxbright AB (publ) | -2.79 Million SEK | 673.39% |
| Mentice AB (publ) | 236.38 Million SEK | 93.216% |
| OssDsign AB (publ) | 83.64 Million SEK | 80.827% |
| Paxman AB (publ) | 12.61 Million SEK | -27.096% |
| Promimic AB (publ) | 38.51 Million SEK | 58.362% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 131.598% |
| ScandiDos AB (publ) | 47.55 Million SEK | 66.277% |
| Sectra AB (publ) | 557.55 Million SEK | 97.124% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 85.285% |
| Senzime AB (publ) | 8.33 Million SEK | -92.313% |
| SpectraCure AB (publ) | -9.22 Million SEK | 273.881% |
| Stille AB | 132.17 Million SEK | 87.866% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.189% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 96.153% |